Riding on third-quarter profits that surprised some analysts thanks to the sale of its spray drug for menopause symptoms earlier this year, Vivus Inc. began the first of two pivotal Phase III trials with Qnexa, the combination phentermine/topiramate drug dosed once daily for obesity. (BioWorld Today) Read More
